According to the Zhitong Finance App, Weilizhibo-B (09887.HK) announced that the 67th ASH Annual Meeting will be held in Orlando, Florida, USA from December 6 to 9, 2025. LBL-034, a GPRC5D/CD3 bispecific antibody independently developed by the company to treat relapsed/refractory multiple myeloma (“RRMM”), gave an oral presentation for the first time on the first day of the conference.

According to the Zhitong Finance App, Weilizhibo-B (09887.HK) announced that the 67th ASH Annual Meeting will be held in Orlando, Florida, USA from December 6 to 9, 2025. LBL-034, a GPRC5D/CD3 bispecific antibody independently developed by the company to treat relapsed/refractory multiple myeloma (“RRMM”), gave an oral presentation for the first time on the first day of the conference.